Eduardo Olavarría

11.4k total citations · 1 hit paper
143 papers, 6.1k citations indexed

About

Eduardo Olavarría is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Eduardo Olavarría has authored 143 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Hematology, 55 papers in Genetics and 36 papers in Oncology. Recurrent topics in Eduardo Olavarría's work include Chronic Myeloid Leukemia Treatments (57 papers), Hematopoietic Stem Cell Transplantation (52 papers) and Chronic Lymphocytic Leukemia Research (45 papers). Eduardo Olavarría is often cited by papers focused on Chronic Myeloid Leukemia Treatments (57 papers), Hematopoietic Stem Cell Transplantation (52 papers) and Chronic Lymphocytic Leukemia Research (45 papers). Eduardo Olavarría collaborates with scholars based in United Kingdom, Spain and Germany. Eduardo Olavarría's co-authors include Jane F. Apperley, John M. Goldman, Richard Szydlo, Jaspal Kaeda, Francesco Dazzi, Charles Craddock, David Marín, Marco Bua, Nicholas C.P. Cross and Dragana Milojković and has published in prestigious journals such as New England Journal of Medicine, The Lancet and The Journal of Experimental Medicine.

In The Last Decade

Eduardo Olavarría

136 papers receiving 6.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)

2007 486 citations Johan Maertens, Eduardo Olavarría et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eduardo Olavarría United Kingdom	41	4.0k	2.3k	1.6k	1.3k	1.2k	143	6.1k
Andrew Grigg Australia	48	5.0k 1.2×	3.8k 1.6×	1.8k 1.2×	2.2k 1.7×	814 0.7×	274	8.8k
Andreas Buser Switzerland	30	2.9k 0.7×	3.2k 1.4×	1.3k 0.8×	1.4k 1.1×	446 0.4×	151	6.2k
Jerzy Hołowiecki Poland	28	1.8k 0.5×	1.5k 0.6×	528 0.3×	1.4k 1.1×	1.1k 1.0×	139	4.8k
Renato Fanin Italy	42	3.6k 0.9×	1.4k 0.6×	445 0.3×	2.0k 1.6×	665 0.6×	226	6.6k
Anthony P. Schwarer Australia	29	2.1k 0.5×	1.1k 0.5×	656 0.4×	591 0.5×	535 0.5×	119	3.3k
Dietrich W. Beelen Germany	45	5.2k 1.3×	1.4k 0.6×	365 0.2×	1.5k 1.2×	991 0.8×	322	7.4k
Rainer Schwerdtfeger Germany	43	4.3k 1.1×	1.2k 0.5×	248 0.2×	1.4k 1.1×	860 0.7×	126	6.0k
George E. Sale United States	37	4.5k 1.1×	1.1k 0.5×	294 0.2×	1.7k 1.3×	1.0k 0.9×	97	7.4k
William Arcese Italy	47	8.9k 2.2×	2.6k 1.1×	523 0.3×	2.6k 2.1×	1.0k 0.9×	257	11.0k
Ryotaro Nakamura United States	41	3.0k 0.8×	1.0k 0.4×	226 0.1×	949 0.7×	1.0k 0.9×	219	5.6k

Countries citing papers authored by Eduardo Olavarría

Since Specialization

Citations

This map shows the geographic impact of Eduardo Olavarría's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eduardo Olavarría with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eduardo Olavarría more than expected).

Fields of papers citing papers by Eduardo Olavarría

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eduardo Olavarría. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eduardo Olavarría. The network helps show where Eduardo Olavarría may publish in the future.

Co-authorship network of co-authors of Eduardo Olavarría

This figure shows the co-authorship network connecting the top 25 collaborators of Eduardo Olavarría. A scholar is included among the top collaborators of Eduardo Olavarría based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eduardo Olavarría. Eduardo Olavarría is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hastings, Andrew K., et al.. (2023). A retrospective analysis to evaluate if KIR B haplotype donors associate with a reduced risk of relapse in patients with haematological malignancies following haploidentical transplantation at the Blood and Bone Marrow Transplant Unit at Hammersmith Hospital ICHNHST. HLA. 103(1). e15214–e15214.

Innes, Andrew J., Benjamin H. Mullish, Rohma Ghani, et al.. (2021). Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation. Frontiers in Cellular and Infection Microbiology. 11. 684659–684659. 23 indexed citations

Dignan, Fiona L., Angela Hamblin, Jungwha Lee, et al.. (2020). Survivorship care for allogeneic transplant patients in the UK NHS: changes centre practice, impact of health service policy and JACIE accreditation over 5 years. Bone Marrow Transplantation. 56(3). 673–678. 7 indexed citations

Szydlo, Richard, Mary Hickson, Andrew J. Innes, et al.. (2018). Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies. Clinical Nutrition. 38(2). 738–744. 40 indexed citations

Roy, Denis‐Claude, S Lachance, Jean Roy, et al.. (2016). Donor lymphocytes depleted of alloreactive T-cells (ATIR101) improve overall survival and reduce transplant related mortality in a T-cell depleted haploidentical HSCT: Results from a Phase 2 trial in patients with AML and ALL. Bone Marrow Transplantation. 51.

Nicolini, Franck E., Grzegorz Basak, Dong‐Wook Kim, et al.. (2015). The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation. Blood. 126(23). 480–480. 6 indexed citations

Mateos, María‐Victoria, Miguel‐Teodoro Hernández, Pilar Giraldo, et al.. (2013). Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma. New England Journal of Medicine. 369(5). 438–447. 348 indexed citations

Kröger, Nicolaus, Ulrike Bacher, Peter Bader, et al.. (2010). NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, Acute Leukemias, and Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation. 16(9). 1187–1211. 60 indexed citations

Lavallade, Hugues de, Jane F. Apperley, Jamshid S. Khorashad, et al.. (2008). Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis. Journal of Clinical Oncology. 26(20). 3358–3363. 416 indexed citations

10.

Khorashad, Jamshid S., Hugues de Lavallade, Jane F. Apperley, et al.. (2008). Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression. Journal of Clinical Oncology. 26(29). 4806–4813. 144 indexed citations

11.

Gabriel, Ian H, Eduardo Olavarría, Amin Rahemtulla, et al.. (2008). Efficacy, Complication Rates, and Cost Effectiveness of Chemotherapy Plus Granulocyte Colony Stimulating Factor Conditioned Mobilisation of Peripheral Blood Haematopoietic Stem Cells in Over 150 Patients with Haematological Malignancies. Blood. 112(11). 2378–2378. 5 indexed citations

12.

Perz, Jolanta B., David Marin, Richard Szydlo, et al.. (2007). Incidence of hyperthyroidism after unrelated donor allogeneic stem cell transplantation. Leukemia Research. 31(10). 1433–1436. 4 indexed citations

13.

Olavarría, Eduardo, et al.. (2007). Case 33. Diagnostic difficulty in a patient with acute leukemia. Leukemia & lymphoma. 48(1). 177–179. 3 indexed citations

14.

Lavallade, Hugues de, Jamshid S. Khorashad, Marco Bua, et al.. (2007). Long Term Durability of Major Molecular Responses for Patients Treated with Imatinib after Failure of Interferon-Alfa Is Equivalent to That of Patients Achieving Major Molecular Responses to Imatinib as Primary Therapy.. Blood. 110(11). 1037–1037. 1 indexed citations

15.

Wain, E. Mary, Eduardo Olavarría, Jane F. Apperley, et al.. (2004). Autologous stem cell transplantation in tumour-stage mycosis fungoides: histological and immunophenotypic features as predictors of outcome. British Journal of Dermatology. 151. 4–5. 3 indexed citations

16.

Terpos, Evangelos, Marianna Politou, Richard Szydlo, et al.. (2004). Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. Leukemia. 18(8). 1420–1426. 51 indexed citations

17.

Marín, David, et al.. (2002). Use of imatinib mesylate in patients with CML in chronic phase resistant to interferon-alfa: Factors defined at start of therapy that predict disease progression and survival. 1 indexed citations

18.

Craddock, Charles, Richard Szydlo, Francesco Dazzi, et al.. (2001). Cytomegalovirus seropositivity adversely influences outcome after T‐depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft‐versus‐host disease prophylaxis. British Journal of Haematology. 112(1). 228–236. 91 indexed citations

19.

Dazzi, Francesco, Richard Szydlo, Charles Craddock, et al.. (2000). Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood. 95(1). 67–71. 10 indexed citations

20.

Olavarría, Eduardo, et al.. (1994). [Evolutive epidemiologic profile of myelodysplastic syndromes (1959-1993). Comparative study with acute myeloid leukemia and aplastic pancytopenias].. PubMed. 39(6). 441–8. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact